We conclude that MRPL21 is a novel biomarker and therapeutic target of HNSCC progression and cisplatin resistant, which may provide a new approach for overcoming cisplatin resistance in HNSCC patients. The gene discussed is MRPL21; the disease is head and neck squamous cell carcinoma.